(Q40813729)

24 September 2017

title

Decreased topoisomerase IIalpha expression confers increased resistance to ICRF-193 as well as VP-16 in mouse embryonic stem cells (English)

1 reference

24 September 2017

1 reference

Kobayashi M

1 reference

24 September 2017

Adachi N

1 reference

24 September 2017

Aratani Y

1 reference

24 September 2017

Kikuchi A

1 reference

24 September 2017

Koyama H

1 reference

24 September 2017

language of work or name

English

0 references

publication date

1 May 2001

1 reference

24 September 2017

1 reference

24 September 2017

volume

166

1 reference

24 September 2017

1 reference

24 September 2017

page(s)

71-77

1 reference

Antitopoisomerase drug action and resistance

24 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2801%2900447-5

7 January 2021

DNA topoisomerase poisons as antitumor drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2801%2900447-5

7 January 2021

Antitumor bisdioxopiperazines inhibit yeast DNA topoisomerase II by trapping the enzyme in the form of a closed protein clamp

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2801%2900447-5

7 January 2021

Catalytic inhibitors of DNA topoisomerase II

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2801%2900447-5

7 January 2021

Expression of a multidrug-resistance gene in human tumors and tissues

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2801%2900447-5

7 January 2021

Response to ICRF-159 in cell lines resistant to cleavable complex-forming topoisomerase II inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2801%2900447-5

7 January 2021

Characterization of a Chinese hamster ovary cell line with acquired resistance to the bisdioxopiperazine dexrazoxane (ICRF-187) catalytic inhibitor of topoisomerase II.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2801%2900447-5

7 January 2021

Yeast cells expressing differential levels of human or yeast DNA topoisomerase II: a potent tool for identification and characterization of topoisomerase II-targeting antitumour agents

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2801%2900447-5

7 January 2021

Characterization of cDNA encoding the mouse DNA topoisomerase II that can complement the budding yeast top2 mutation

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2801%2900447-5

7 January 2021

Structural organization of the human TOP2A and TOP2B genes.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2801%2900447-5

7 January 2021

Effects of DNA topoisomerase inhibitors on nonhomologous and homologous recombination in mammalian cells

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2801%2900447-5

7 January 2021

Characterization of the 3' untranslated region of mouse DNA topoisomerase IIalpha mRNA.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2801%2900447-5

7 January 2021

Mutant isolation of mouse DNA topoisomerase II alpha in yeast

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2801%2900447-5

7 January 2021

Production of homozygous mutant ES cells with a single targeting construct

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2801%2900447-5

7 January 2021

A novel mechanism of cell killing by anti-topoisomerase II bisdioxopiperazines

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2801%2900447-5

7 January 2021

10.1016/S0304-3835(01)00447-5

Identifiers

DOI

1 reference

24 September 2017

1 reference